Search Within

Terence John Purdon

Formats
  1. Meeting Abstract (39)
  2. Journal Article (22)
Groups
  1. Adult Leukemia (61)
  2. Center for Hematologic Malignancies (61)
  3. Department of Medicine (61)
  4. GSK Faculty (61)
  5. Hematologic Malignancies Research (61)
  6. Hematologic Malignancies, Division of (61)

More Groups

People
  1. Renier Brentjens (60)
  2. Isabelle Riviere (30)
  3. Jae Park (28)
  4. Xiuyan Wang (25)
  5. Michel Sadelain (22)
  6. Kevin Curran (18)

More People

Years
  1. 2022 (1)
  2. 2021 (5)
  3. 2020 (7)
  4. 2019 (7)
  5. 2018 (11)
  6. 2017 (11)

More Years

Publications
  1. Blood (15)
  2. Journal of Clinical Oncology (8)
  3. Molecular Therapy (7)
  4. Cancer Immunology Research (4)
  5. Cytotherapy (3)
  6. Leukemia (3)

More Publications

Publishers
  1. American Society of Hematology (16)
  2. Nature Publishing Group (14)
  3. American Association for Cancer Research (8)
  4. American Society of Clinical Oncology (8)
  5. Elsevier Science Ltd. (3)
  6. Cell Press (2)

More Publishers

Results (61)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Durable long-term survival of adult patients with B-ALL after CD19 CAR (19-28z) T cell therapy
    Meeting Abstract

    Park, J.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Purdon, T.; Brentjens, R.; Sadelain, M.
    Haematologica (2017)

    Fulltext@MSK | Save
  • A Phase I trial of 19-28z CAR-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Updated results: Phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy
    Meeting Abstract

    Geyer, M. B.; Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL
    Meeting Abstract

    Geyer, M. B.; Park, J. H.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T. J.; Sadelain, M. W.; Brentjens, R. J.
    Blood (2016)

    Fulltext@MSK | Save
  • IL-18 secreting CAR T cells enhance cell persistence, induce prolonged B cell aplasia and eradicate CD19+ tumor cells without need for prior conditioning
    Meeting Abstract

    Avanzi, M. P.; van Leeuwen, D. G.; Li, X.; Cheung, K.; Park, H.; Purdon, T. J.; Brentjens, R. J.
    Blood (2016)

    Fulltext@MSK | Save
  • CD33-directed chimeric antigen receptor (CAR) T cells for the treatment of acute myeloid leukemia (AML)
    Meeting Abstract

    Rafiq, S.; Purdon, T. J.; Schultz, L. M.; Brentjens, R. J.
    Blood (2016)

    Fulltext@MSK | Save
  • Phase I trial: CD19-targeted CAR T-cells in patients with residual CLL following initial purine analog-based therapy
    Meeting Abstract

    Geyer, M.; Park, J.; RivieĢ€re, I.; Senechal, B.; Hsu, M.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R.
    Clinical Lymphoma, Myeloma and Leukemia (2016)

    Fulltext@MSK | Save
  • Engineering armored T cell receptor-mimic (TCRm) chimeric antigen receptor (CAR) T cells specific for the intracellular protein Wilms tumor 1 (WT1) for treatment of hematologic and solid malignancies
    Meeting Abstract

    Rafiq, S.; Purdon, T.; Dao, T.; Liu, C.; Scheinberg, D.; Brentjens, R. J.
    Molecular Therapy (2016)

    Fulltext@MSK | Save
  • Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Wang, Y.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; more...
    Blood (2015)

    Fulltext@MSK | Save